journal
https://read.qxmd.com/read/33397141/subjective-responses-to-alcohol-in-the-development-and-maintenance-of-alcohol-use-disorder
#1
Andrea King, Ashley Vena, Deborah S Hasin, Harriet deWit, Sean J O'Connor, Dingcai Cao
OBJECTIVE: Alcohol use disorder (AUD) remains an urgent public health problem. Longitudinal data are needed to clarify the role of acute subjective responses to alcohol in the development and maintenance of excessive drinking and AUD. The authors report on 10 years of repeated examination of acute alcohol responses in the Chicago Social Drinking Project. METHODS: Young adult drinkers (N=190) participated in an initial alcohol challenge (0.8 g/kg of alcohol compared with placebo) that was repeated 5 and 10 years later...
January 5, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33397140/neuroimaging-biomarkers-in-schizophrenia
#2
Nina V Kraguljac, William M McDonald, Alik S Widge, Carolyn I Rodriguez, Mauricio Tohen, Charles B Nemeroff
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological, and phenotypic profile. Currently, no objective biological measures-that is, biomarkers-are available to inform diagnostic or treatment decisions. Neuroimaging is well positioned for biomarker development in schizophrenia, as it may capture phenotypic variations in molecular and cellular disease targets, or in brain circuits. These mechanistically based biomarkers may represent a direct measure of the pathophysiological underpinnings of the disease process and thus could serve as true intermediate or surrogate endpoints...
January 5, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33397139/a-randomized-controlled-trial-of-repeated-ketamine-administration-for-chronic-posttraumatic-stress-disorder
#3
Adriana Feder, Sara Costi, Sarah B Rutter, Abigail B Collins, Usha Govindarajulu, Manish K Jha, Sarah R Horn, Marin Kautz, Morgan Corniquel, Katherine A Collins, Laura Bevilacqua, Andrew M Glasgow, Jess Brallier, Robert H Pietrzak, James W Murrough, Dennis S Charney
OBJECTIVE: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD...
January 5, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33297720/reducing-adolescent-psychopathology-in-socioeconomically-disadvantaged-children-with-a-preschool-intervention-a-randomized-controlled-trial
#4
Karen L Bierman, Brenda S Heinrichs, Janet A Welsh, Robert L Nix
OBJECTIVE: Living in poverty increases exposure to adversities that undermine healthy development, impeding growth in the social-emotional and language skills that support adaptive coping and promote mental health. Evidence-based programs have the potential to improve current preschool practice and strengthen these early skills, potentially reducing risk for later psychopathology. The authors tested the hypothesis that an enrichment program in preschool would be associated with reduced levels of psychopathology symptoms at the transition from middle to secondary school...
December 10, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33297719/ulipristal-acetate-for-treatment-of-premenstrual-dysphoric-disorder-a-proof-of-concept-randomized-controlled-trial
#5
Erika Comasco, Helena Kopp Kallner, Marie Bixo, Angelica L Hirschberg, Sara Nyback, Haro de Grauw, C Neill Epperson, Inger Sundström-Poromaa
OBJECTIVE: Premenstrual dysphoric disorder (PMDD) is a common mood disorder, characterized by distressing affective, behavioral, and somatic symptoms in the late luteal phase of the menstrual cycle. The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD. METHODS: The authors conducted an investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial in which women with PMDD (N=95) were treated with either 5 mg/day of UPA or placebo during three 28-day treatment cycles...
December 10, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33207936/association-of-inflammatory-activity-with-larger-neural-responses-to-threat-and-reward-among-children-living-in-poverty
#6
Gregory E Miller, Stuart F White, Edith Chen, Robin Nusslock
OBJECTIVE: Children exposed to severe, chronic stress are vulnerable to mental and physical health problems across the lifespan. To explain how these problems develop, the neuroimmune network hypothesis suggests that early-life stress initiates a positive feedback loop between peripheral inflammatory cells and networked brain regions involved in threat and reward processing. The authors sought to test this hypothesis by studying a sample of urban children from diverse socioeconomic backgrounds...
November 19, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33207935/moderation-of-prazosin-s-efficacy-by-alcohol-withdrawal-symptoms
#7
Rajita Sinha, Stephanie Wemm, Nia Fogelman, Verica Milivojevic, Peter M Morgan, Gustavo A Angarita, Gretchen Hermes, Helen C Fox
OBJECTIVE: Alcohol use disorder (AUD) is a leading cause of global disease burden. Chronic, heavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of alcohol craving and mood, anxiety, and sleep disturbances, which are predictive of poor treatment outcomes. The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in reducing alcohol intake and associated secondary outcomes. METHODS: A 12-week, double-blind, randomized, controlled proof-of-concept trial of prazosin (16 mg/day, with a 2-week titration) was conducted in community-recruited adults with current alcohol dependence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry...
November 19, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33167675/electroconvulsive-therapy-in-mania-a-review-of-80-years-of-clinical-experience
#8
Alby Elias, Naveen Thomas, Harold A Sackeim
Resistance to pharmacological agents is commonly encountered in the treatment of acute episodes of mania. In contemporary practice guidelines, electroconvulsive therapy (ECT), once a widely used standalone intervention for mania, is no longer considered a first-line treatment. Stigma, logistics, and ethical factors constrain ECT administration in this condition and lead to its underutilization. However, the past three decades have produced promising research regarding the use of ECT in mania. Randomized controlled trials, albeit in limited numbers, the adoption of ultrabrief ECT, examination of the safety and efficacy of combining ECT with pharmacological agents, including lithium, and use of ECT as a maintenance strategy have enhanced our understanding of how and when to utilize this intervention in mania...
November 10, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33167674/contraception-for-women-with-psychiatric-disorders
#9
Leanne R McCloskey, Katherine L Wisner, Minaz Kolia Cattan, Hannah K Betcher, Catherine S Stika, Jessica W Kiley
OBJECTIVE: Mental health care for women includes decision support to prepare for major life events, including preconception planning for treatment during pregnancy and the postpartum period. The authors discuss contraceptive choices and their effectiveness, side effects, and impact on psychiatric symptoms. The Centers for Disease Control and Prevention's recommendations, Medical Eligibility Criteria for Contraceptive Use, provided the structure for review of contraceptive choices. METHODS: A search of PsycINFO, PubMed, Embase, and Scopus was conducted for publications on the management of contraception for women with mental illness...
November 10, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33167673/learning-about-safety-conditioned-inhibition-as-a-novel-approach-to-fear-reduction-targeting-the-developing-brain
#10
Paola Odriozola, Dylan G Gee
Adolescence is a peak time for the onset of psychiatric disorders, with anxiety disorders being the most common and affecting as many as 30% of youths. A core feature of anxiety disorders is difficulty regulating fear, with evidence suggesting deficits in extinction learning and corresponding alterations in frontolimbic circuitry. Despite marked changes in this neural circuitry and extinction learning throughout development, interventions for anxious youths are largely based on principles of extinction learning studied in adulthood...
November 10, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33138631/understanding-the-clinical-effects-and-mechanisms-of-action-of-neurosteroids
#11
Robert A Kleinman, Alan F Schatzberg
No abstract text is available yet for this article.
November 3, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33115247/quality-of-outpatient-depression-treatment-in-patients-with-comorbid-substance-use-disorder
#12
Lara N Coughlin, Paul Pfeiffer, Dara Ganoczy, Lewei A Lin
OBJECTIVE: Clinical practice guidelines recommend concurrent treatment of co-occurring depression and substance use disorders; however, the degree to which patients with substance use disorders receive guideline-concordant treatment for depression is unknown. The authors investigated the provision of guideline-concordant depression treatment to patients with and without substance use disorders in a large integrated health care system. METHODS: In a retrospective cohort study of 53,034 patients diagnosed with a depressive disorder in fiscal year 2017 in the U...
October 29, 2020: American Journal of Psychiatry
https://read.qxmd.com/read/33384013/a-genetics-first-approach-to-dissecting-the-heterogeneity-of-autism-phenotypic-comparison-of-autism-risk-copy-number-variants
#13
Samuel J R A Chawner, Joanne L Doherty, Richard J L Anney, Kevin M Antshel, Carrie E Bearden, Raphael Bernier, Wendy K Chung, Caitlin C Clements, Sarah R Curran, Goran Cuturilo, Ania M Fiksinski, Louise Gallagher, Robin P Goin-Kochel, Raquel E Gur, Ellen Hanson, Sebastien Jacquemont, Wendy R Kates, Leila Kushan, Anne M Maillard, Donna M McDonald-McGinn, Marina Mihaljevic, Judith S Miller, Hayley Moss, Milica Pejovic-Milovancevic, Robert T Schultz, LeeAnne Green-Snyder, Jacob A Vorstman, Tara L Wenger, Jeremy Hall, Michael J Owen, Marianne B M van den Bree
OBJECTIVE: Certain copy number variants (CNVs) greatly increase the risk of autism. The authors conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype relationships. METHODS: This international study included 547 individuals (mean age, 12.3 years [SD=4.2], 54% male) who were ascertained on the basis of having a genetic diagnosis of a rare CNV associated with high risk of autism (82 16p11...
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384012/autism-spectrum-disorder-genetics-and-the-search-for-pathological-mechanisms
#14
Devanand S Manoli, Matthew W State
Recent progress in the identification of genes and genomic regions contributing to autism spectrum disorder (ASD) has had a broad impact on our understanding of the nature of genetic risk for a range of psychiatric disorders, on our understanding of ASD biology, and on defining the key challenges now facing the field in efforts to translate gene discovery into an actionable understanding of pathology. While these advances have not yet had a transformative impact on clinical practice, there is nonetheless cause for real optimism: reliable lists of risk genes are large and growing rapidly; the identified encoded proteins have already begun to point to a relatively small number of areas of biology, where parallel advances in neuroscience and functional genomics are yielding profound insights; there is strong evidence pointing to mid-fetal prefrontal cortical development as one nexus of vulnerability for some of the largest-effect ASD risk genes; and there are multiple plausible paths forward toward rational therapeutics development that, while admittedly challenging, constitute fundamental departures from what was possible prior to the era of successful gene discovery...
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384011/is-valproate-reasonable
#15
LETTER
Nicole Leistikow, Milena H Smith, Jennifer L Payne, Lauren M Osborne
No abstract text is available yet for this article.
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384010/is-valproate-reasonable-response-to-leistikow-et-al
#16
LETTER
Rita Suri, Donna Kanar Socol, Michael Gitlin
No abstract text is available yet for this article.
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384009/can-transgenic-monkeys-help-us-innovate-transdiagnostic-therapies
#17
EDITORIAL
Odile A van den Heuvel
No abstract text is available yet for this article.
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384008/pandas-too-narrow-a-view-of-the-neuroimmune-landscape
#18
EDITORIAL
Steven E Hyman
No abstract text is available yet for this article.
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384007/harmonizing-the-neurobiology-and-treatment-of-obsessive-compulsive-disorder
#19
Wayne K Goodman, Eric A Storch, Sameer A Sheth
Obsessive-compulsive disorder (OCD) is a common, chronic, and oftentimes disabling disorder. The only established first-line treatments for OCD are exposure and response prevention, and serotonin reuptake inhibitor medications (SRIs). However, a subset of patients fails to respond to either modality, and few experience complete remission. Beyond SRI monotherapy, antipsychotic augmentation is the only medication approach for OCD with substantial empirical support. Our incomplete understanding of the neurobiology of OCD has hampered efforts to develop new treatments or enhance extant interventions...
January 1, 2021: American Journal of Psychiatry
https://read.qxmd.com/read/33384006/genotype-phenotype-predictions-in-autism-are-we-there-yet
#20
EDITORIAL
Elisabeth B Binder
No abstract text is available yet for this article.
January 1, 2021: American Journal of Psychiatry
journal
journal
20277
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"